Focused On-demand Library for Mitochondrial import inner membrane translocase subunit TIM14

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q96DA6

UPID:

TIM14_HUMAN

Alternative names:

DnaJ homolog subfamily C member 19

Alternative UPACC:

Q96DA6; B2R4B1; C9JBV1

Background:

Mitochondrial import inner membrane translocase subunit TIM14, also known as DnaJ homolog subfamily C member 19, plays a crucial role in mitochondrial function. It is involved in the formation of a complex with prohibitins that is essential for cardiolipin remodeling. This protein is potentially a component of the PAM complex, facilitating the translocation of proteins into the mitochondrial matrix in an ATP-dependent manner.

Therapeutic significance:

Linked to 3-methylglutaconic aciduria 5, a disorder characterized by dilated cardiomyopathy, cerebellar ataxia, and metabolic anomalies, TIM14's genetic variants highlight its therapeutic significance. Understanding the role of TIM14 could open doors to potential therapeutic strategies for treating mitochondrial disorders and related metabolic conditions.